# PTM Biolabs

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ptm-biolabs

- Industry: Biotechnology
- Headquarters: Hangzhou, China
- Website: www.ptm-biolab.com.cn
- Total disclosed funding: $80M
- Latest round: Series B (Nov 12, 2020)
- Investors on record: 6

## About

Established in 2011 and based in Hangzhou, China. PTM Biolabs Inc. is a biotechnology company that focuses on research and development of biological antibodies and biological monitoring applications. The company is headquartered in Hangzhou, with offices in Beijing, Shanghai, Guangzhou, Nanjing, Wuhan and Chengdu. The company was approved as a high-tech research and development center in Zhejiang Province in 2020.

The company is engaged in biomarker discovery drug discovery, diagnostic kit development and other related research oriented by gene proteomics and histone cryptomics. Its self-developed technology platforms include an epigenetics technology platform, a gene proteomics technology platform, a high-quality antibody platform, a diagnostic kit platform, and a big data platform.

## Funding rounds

- Series B, Nov 12, 2020, $80M — IDG Capital, Fortune Capital, HighLight Capital, Zhuhai Longmen Capital Management, SDIC Venture Capital
- Series A, Apr 15, 2020 — SDIC Venture Capital, BioTrack Capital

## Investors

- SDIC Venture Capital (https://capitalatlas.ai/funds/sdic-venture-capital) — Series A, Series B
- BioTrack Capital (https://capitalatlas.ai/funds/biotrack-capital) — Series A
- IDG Capital (https://capitalatlas.ai/funds/idg-capital) — Series B
- Fortune Capital — Series B
- HighLight Capital (https://capitalatlas.ai/funds/highlight-capital) — Series B
- Zhuhai Longmen Capital Management (https://capitalatlas.ai/funds/zhuhai-longmen-capital-management) — Series B